Sub menu

 
 

BORTEZOMIB-TEVA (Teva Pharma Australia Pty Ltd)

Product name
BORTEZOMIB-TEVA
Sponsor
Teva Pharma Australia Pty Ltd
Date registered
Evaluation commenced
Decision date
Approval time
250 working days (255)
Active ingredients
bortezomib
Registration type
New generic medicine
Indication

BORTEZOMIB-TEVA (powder for injection), in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.

BORTEZOMIB-TEVA, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.

BORTEZOMIB-TEVA is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.

BORTEZOMIB-TEVA in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Help us improve the Therapeutic Goods Administration site